- Home
- IBTA vs CDNA Comparison
IBTA vs CDNA Comparison
Compare IBTA & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- CDNA
- Stock Information
- Founded
- IBTA 2011
- CDNA 1998
- Country
- IBTA United States
- CDNA United States
- Employees
- IBTA N/A
- CDNA N/A
- Industry
- IBTA
- CDNA Medical Specialities
- Sector
- IBTA
- CDNA Health Care
- Exchange
- IBTA Nasdaq
- CDNA Nasdaq
- Market Cap
- IBTA 892.4M
- CDNA 1.0B
- IPO Year
- IBTA 2024
- CDNA 2014
- Fundamental
- Price
- IBTA $40.05
- CDNA $12.79
- Analyst Decision
- IBTA Buy
- CDNA Buy
- Analyst Count
- IBTA 10
- CDNA 6
- Target Price
- IBTA $74.60
- CDNA $29.33
- AVG Volume (30 Days)
- IBTA 369.9K
- CDNA 2.2M
- Earning Date
- IBTA 08-13-2025
- CDNA 08-06-2025
- Dividend Yield
- IBTA N/A
- CDNA N/A
- EPS Growth
- IBTA 24.66
- CDNA N/A
- EPS
- IBTA 2.03
- CDNA 1.07
- Revenue
- IBTA $369,501,000.00
- CDNA $346,421,000.00
- Revenue This Year
- IBTA $6.89
- CDNA $13.31
- Revenue Next Year
- IBTA $15.55
- CDNA $15.46
- P/E Ratio
- IBTA $19.69
- CDNA $11.90
- Revenue Growth
- IBTA 7.20
- CDNA 25.92
- 52 Week Low
- IBTA $31.40
- CDNA $10.96
- 52 Week High
- IBTA $79.80
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- CDNA 29.88
- Support Level
- IBTA N/A
- CDNA $11.62
- Resistance Level
- IBTA N/A
- CDNA $13.40
- Average True Range (ATR)
- IBTA 0.00
- CDNA 1.31
- MACD
- IBTA 0.00
- CDNA -0.66
- Stochastic Oscillator
- IBTA 0.00
- CDNA 18.39
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.